The Impact of Cost of Living on the Quality of Life of Cystic Fibrosis Patients: A Study in Greece.

cost of living cystic fibrosis (cf) general health questionnaire physical functioning quality of life (qol)

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Jun 2024
Historique:
accepted: 23 06 2024
medline: 26 7 2024
pubmed: 26 7 2024
entrez: 25 7 2024
Statut: epublish

Résumé

Introduction Cystic fibrosis (CF) leads to the impairment of multiple essential organs and systems in the human body. The objective of this study was to analyze the financial consequences of having cystic fibrosis (CF) on patients, evaluate their general state of health, and specifically investigate the impact of living expenses on their quality of life. Methods The data were collected using three tools and a form for personal information entry. The first questionnaire was employed to quantify fluctuations in patients' cost of living. The Greek variant of the Short Form Questionnaire-36 (SF-36) and the Greek version of the Cystic Fibrosis Quality of Life (CFQoL) were implemented to assess quality of life. Statistical significance was set at p < 0.05, and analyses were conducted using SPSS statistical software. Results The study obtained a response rate of 93.2%, with 105 participants consenting to and effectively finishing the questionnaire. The mean age of the patients was 32.1 years, with 46.7% being female and 53.3% being male. Medication was being administered to 46.7% of the patients. The condition incurred an average cost of 767€ in the preceding semester. The maximum cost was 1007€. Patients with a higher monthly family income and those who were taking medication exhibited superior physical performance and functional capacity. Conclusion The research emphasizes that implementing causative treatment and minimizing hospitalizations can potentially enhance life satisfaction. The findings suggest possible approaches to enhance the quality of life in people with cystic fibrosis, in conjunction with the implementation of novel or enhanced treatment modalities.

Identifiants

pubmed: 39050347
doi: 10.7759/cureus.63009
pmc: PMC11267247
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e63009

Informations de copyright

Copyright © 2024, Dainavas et al.

Déclaration de conflit d'intérêts

Human subjects: Consent was obtained or waived by all participants in this study. Ethics Committee of the Department of Nursing of the National Kapodistrian University of Athens issued approval (322/10-06-2020). The Ethics Committee of the Department of Nursing of the National Kapodistrian University of Athens granted ethical approval for this study (322/10-06-2020). Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Références

Chest. 2007 Jul;132(1):231-7
pubmed: 17625085
Am J Respir Crit Care Med. 2008 Nov 1;178(9):921-8
pubmed: 18658109
Chest. 2007 Apr;131(4):1224-31
pubmed: 17426231
J Cyst Fibros. 2008 Sep;7(5):403-8
pubmed: 18358793
Pol Merkur Lekarski. 2007 Aug;23(134):137-40
pubmed: 18044346
Health Qual Life Outcomes. 2004 Nov 22;2:66
pubmed: 15555077
Qual Life Res. 2005 Jun;14(5):1433-8
pubmed: 16047519
Expert Opin Pharmacother. 2008 Apr;9(5):751-66
pubmed: 18345953
Pharmacoeconomics. 2012 Sep 1;30(9):763-77
pubmed: 22690685
Thorax. 1998 Sep;53(9):727-31
pubmed: 10319053
Chest. 2003 Jan;123(1):42-8
pubmed: 12527601
Klin Padiatr. 2006 Jan-Feb;218(1):7-12
pubmed: 16432767
J Cyst Fibros. 2020 May;19(3):344-354
pubmed: 32115388
Thorax. 2000 Nov;55(11):946-54
pubmed: 11050265
J Cyst Fibros. 2015 May;14(3):384-91
pubmed: 25620688
J Trauma Nurs. 2014 May-Jun;21(3):115-21
pubmed: 24828773
Value Health. 2012 Mar-Apr;15(2):277-83
pubmed: 22433759
J Cyst Fibros. 2003 Dec;2(4):206-13
pubmed: 15463875
Health Qual Life Outcomes. 2005 Mar 24;3:19
pubmed: 15790407
J Pediatr. 2008 Aug;153(2):S4-S14
pubmed: 18639722
Pediatr Pulmonol. 2011 Aug;46(8):770-6
pubmed: 21465674
Int J Technol Assess Health Care. 2006 Fall;22(4):525-31
pubmed: 16984688
N Engl J Med. 2006 Jan 19;354(3):229-40
pubmed: 16421364
J Cyst Fibros. 2005 Mar;4(1):59-66
pubmed: 15752683
Chest. 2005 Oct;128(4):2347-54
pubmed: 16236893
Pneumonol Alergol Pol. 2016;84(4):205-11
pubmed: 27435346

Auteurs

Dimitris Dainavas (D)

Department of Nursing, School of Health Sciences, National and Kapodistrian University of Athens, Athens, GRC.

Pantelis Stergiannis (P)

Department of Nursing, School of Health Sciences, National and Kapodistrian University of Athens, Athens, GRC.

Panagiota Manthou (P)

Critical Care Medicine, University of West Attica, Athens, GRC.

Georgios Lioliousis (G)

Intensive Care Unit, 1st Department of Respiratory Medicine, Thoracic Diseases General Hospital Sotiria, National and Kapodistrian University of Athens, Athens, GRC.

Filia Diamantea (F)

Adult Cystic Fibrosis (CF) Unit, Sismanoglio Hospital, Athens, GRC.

Pavlos Myrianthefs (P)

Department of Nursing, School of Health Sciences, National and Kapodistrian University of Athens, Athens, GRC.

Georgios Fildissis (G)

Department of Nursing, School of Health Sciences, National and Kapodistrian University of Athens, Athens, GRC.

Classifications MeSH